In this study, we capitalized on our previously performed crystallographic fragment screen and developed the antitubulin small molecule Todalam with only two rounds of straightforward chemical synthesis. Todalam binds to a novel tubulin site, disrupts microtubule networks in cells, arrests cells in G2/M, induces cell death, and synergizes with vinblastine. The compound destabilizes microtubules by acting as a molecular plug that sterically inhibits the curved-to-straight conformational switch in the α-tubulin subunit, and by sequestering tubulin dimers into assembly incompetent oligomers. Our results describe for the first time the generation of a fully rationally designed small molecule tubulin inhibitor from a fragment, which displays a unique molecular mechanism of action. They thus demonstrate the usefulness of tubulin-binding fragments as valuable starting points for innovative antitubulin drug and chemical probe discovery campaigns.

Muhlethaler, T., Milanos, L., Ortega, J.A., Blum, T.B., Gioia, D., Roy, B., et al. (2022). Rational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action. ANGEWANDTE CHEMIE. INTERNATIONAL EDITION, 61(25), 1-11 [10.1002/anie.202204052].

Rational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action

Gioia D.;Cavalli A.;
2022

Abstract

In this study, we capitalized on our previously performed crystallographic fragment screen and developed the antitubulin small molecule Todalam with only two rounds of straightforward chemical synthesis. Todalam binds to a novel tubulin site, disrupts microtubule networks in cells, arrests cells in G2/M, induces cell death, and synergizes with vinblastine. The compound destabilizes microtubules by acting as a molecular plug that sterically inhibits the curved-to-straight conformational switch in the α-tubulin subunit, and by sequestering tubulin dimers into assembly incompetent oligomers. Our results describe for the first time the generation of a fully rationally designed small molecule tubulin inhibitor from a fragment, which displays a unique molecular mechanism of action. They thus demonstrate the usefulness of tubulin-binding fragments as valuable starting points for innovative antitubulin drug and chemical probe discovery campaigns.
2022
Muhlethaler, T., Milanos, L., Ortega, J.A., Blum, T.B., Gioia, D., Roy, B., et al. (2022). Rational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action. ANGEWANDTE CHEMIE. INTERNATIONAL EDITION, 61(25), 1-11 [10.1002/anie.202204052].
Muhlethaler, T.; Milanos, L.; Ortega, J. A.; Blum, T. B.; Gioia, D.; Roy, B.; Prota, A. E.; Cavalli, A.; Steinmetz, M. O.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/1003311
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 23
social impact